Media Centre
Latest press releases
-
AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19
-
PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma
-
Human ventricular progenitor cells promote the formation of new heart tissue following a heart attack
-
Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
-
Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Amanda Talamonte
Manager, Global Media Relations
+44 (0)1223 344 800
Angela Fiorin
Director, Global Media Relations (Oncology)
+44 (0)1223 344 800
Brendan McEvoy
Head, US External Communications
+1 302 885 2677
Fiona Cookson
Director, Global Media Relations
(COVID-19 and BioPharmaceuticals)
+44 (0)1223 344 800
Flavia Garcia
Manager, Global Media Relations
+44 (0)1223 344 800
Freja Annamatz
Director, Media Relations, Sweden
freja.annamatz@astrazeneca.com
+46 722 084 748
Kim Blomley
Director, Global Media Relations (Corporate)
+44 (0)1223 344 800
Lisa Taylor
Senior Director, Corporate Communications (Alexion)
+1 857 338 9025
Sinead Keller
Director, Global Media Relations
(COVID-19 and BioPharmaceuticals)
+44 (0)1223 344 800
